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Summary
Objective: To evaluate the influence of prior use of carbamazepine (CBZ) and
other antiepileptic drugs (AEDs) with a putatively similar mechanism of action (in-
hibition of voltage-gated sodium channels; VGSCs) on seizure outcomes and tolera-
bility when converting to eslicarbazepine acetate (ESL), using data pooled from 2
controlled conversion-to-ESL monotherapy trials (studies: 093-045, 093-046).
Methods: Adults with treatment-resistant focal (partial-onset) seizures were ran-
domized 2:1 to ESL 1600 or 1200 mg once daily. The primary efficacy endpoint
was study exit (meeting predefined exit criteria related to worsening seizure con-
trol) versus an historical control group. Other endpoints included change in sei-
zure frequency, responder rate, and tolerability. Endpoints were analyzed for
subgroups of patients who received CBZ (or any VGSC inhibitor [VGSCi]) dur-
ing baseline versus those who received other AEDs.
Results: Of 365 patients in the studies, 332 were evaluable for efficacy. The
higher risk of study exit in the subgroups that received CBZ (or any VGSCi) dur-
ing baseline, versus other AEDs, was not statistically significant (hazard ratios
were 1.49 for +CBZ vs CBZ [P = .10] and 1.27 for +VGSCi vs. VGSCi
[P = .33]). Reductions in seizure frequency and responder rates were lower in
patients who converted from CBZ or other VGSCi compared with those who con-
verted from other AEDs. There were no notable differences in overall tolerability
between subgroups, but the incidence of some adverse events (eg, dizziness, som-
nolence, nausea) differed between subgroups and/or between treatment periods.
Significance: Baseline use of CBZ or other major putative VGSC inhibitors did
not appear to significantly increase the risk of study exit due to worsening seizure
control, or to increase the frequency of side effects when converting to ESL
monotherapy. However, bigger improvements in efficacy may be possible in
patients converting to ESL monotherapy from an AED regimen that does not
include a VGSC inhibitor.
KEYWORD S
antiepileptic drugs, focal seizures, refractory epilepsy, switching
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium,
provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
© 2018 The Authors. Epilepsia published by Wiley Periodicals, Inc. on behalf of International League Against Epilepsy.
Accepted: 8 January 2018
DOI: 10.1111/epi.14014
704 | wileyonlinelibrary.com/journal/epi Epilepsia. 2018;59:704–714.
1 | INTRODUCTION
Eslicarbazepine acetate (ESL) is a third-generation member
of the dibenzazepine carboxamide class of antiepileptic
drugs (AEDs), which also includes carbamazepine (CBZ)
and oxcarbazepine (OXC). ESL was approved by the Uni-
ted States Food and Drug Administration (FDA) for
monotherapy following successful completion of 2 conver-
sion-to-monotherapy trials with identical protocols (studies
093-045 and -046).1,2 ESL was subsequently approved by
the European Medicines Agency for use as monotherapy in
adults with newly diagnosed epilepsy.
Studies 045 and 046 demonstrated that conversion to
ESL monotherapy was effective and well tolerated in
patients with focal (partial-onset) seizures not adequately
controlled by 1 or 2 AEDs.1,2 Whether or not prior CBZ use
influences outcomes following conversion to ESL monother-
apy is of interest to practicing clinicians; it is particularly
important given that in previous conversion-to-monotherapy
studies, the effect of converting from CBZ-containing regi-
mens to other AED monotherapies raised the hazard rate of
study exit (due to seizure worsening) by 8%, compared with
converting from regimens that did not contain CBZ.3 In
addition, concomitant use of CBZ together with ESL may
result in plasma eslicarbazepine concentrations that are 20%-
30% less than those observed in patients taking ESL without
concomitant enzyme-inducing AEDs.4 The 2 conversion-to-
ESL monotherapy studies in the current analysis permitted
enrollment of patients taking CBZ,1,2 allowing the influence
of previous exposure to CBZ to be examined.
Both ESL and CBZ are believed to exert their anticonvul-
sant/antiepileptic effects, at least in part, through inhibition of
voltage-gated sodium channels (VGSCs). Clinicians may
therefore question whether differences in seizure control can
be expected following conversion from CBZ to ESL
monotherapy, and if so, what the magnitude of such differ-
ences might be. Notably, recent evidence suggests that there
may be differences between ESL and CBZ with regard to their
interaction with VGSCs. Both agents have relatively higher
affinity for the inactivated state than the resting state of the
channel,5 and so would be expected to reduce high frequency
neuronal firing in a use-dependent fashion. However, the
kinetics of inactivation may differ between the 2 agents; esli-
carbazepine (the primary active metabolite of ESL) does not
appear to be involved in fast inactivation of VGSCs but may
preferentially enhance their slow inactivation, whereas CBZ
alters the fast inactivation of VGSCs but appears to have a les-
ser effect on their slow inactivation (compared with eslicar-
bazepine).6 These differences between the mechanisms of
action (MoAs) of the 2 agents suggest that conversion from
CBZ to ESL monotherapy may be feasible and that such a
conversion could lead to alterations in seizure frequency.
Combining data from studies 045 and 046 allows a
detailed analysis of the efficacy and safety of ESL
monotherapy in patients who were or were not taking base-
line CBZ. The primary objective of the current analysis was
to evaluate whether use of CBZ prior to conversion to ESL
monotherapy affected seizure outcomes and the incidence
of treatment-emergent adverse events (TEAEs) during and
following the conversion, in patients with refractory focal
seizures. To further examine the potential influence of prior
exposure to an agent with a similar MoA, the efficacy and
safety of ESL monotherapy were evaluated in patients who
converted from AEDs with a putatively similar MoA (ie,
AEDs believed to work primarily via VGSC inhibition),
compared with those who converted from regimens that did
not include those agents. CBZ, lamotrigine (LTG), OXC,
and phenytoin (PHT) were the most frequently used base-
line VGSC inhibitors (VGSCi) in the conversion-to-ESL
monotherapy trials, and so were included in this analysis.
The findings of the current analysis may provide addi-
tional insights on the viability of converting to ESL from
AEDs with a putatively similar primary MoA, and/or
whether converting patients from CBZ specifically, to ESL,
poses unique challenges for the physician.
2 | METHODS
2.1 | Standard protocol approvals,
registration, and patient consent
Data were pooled from 2 phase III conversion-to-monother-
apy trials (093-045 [NCT00866775] and 093-046
[NCT01091662], registered at ClinicalTrials.gov) that used
Key Points
• When converting to ESL, the risk of study exit
due to worsening seizure control was not signifi-
cantly higher with baseline use of CBZ or other
VGSC-inhibiting AEDs
• Improvements in seizure frequency and respon-
der rates were numerically lower in patients con-
verting to ESL from baseline CBZ or other
VGSC inhibitors
• ESL was well tolerated regardless of baseline use
of CBZ or other VGSC inhibitors; rates of specific
treatment-emergent adverse events varied between
groups and treatment periods
• Greater improvements in efficacy may be possi-
ble in patients converting to ESL monotherapy
from an AED regimen that does not include
CBZ or other VGSC inhibitors
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a historical control comparator. The trials were conducted
between 2009 and 2013 at sites in the United States,
Canada, Bulgaria, Serbia, the Ukraine, and the Czech
Republic. Both studies were performed in accordance with
the principles of the Declaration of Helsinki, the Interna-
tional Conference on Harmonisation guidelines, and all rel-
evant national, state, and local laws; study protocols were
approved by the relevant independent ethics committees/
institutional review boards, and all patients provided
informed consent.
2.2 | Patients
Eligible patients were aged 16-70 years with treatment-
resistant “partial-onset” seizures (classified according to
the 1981 version of the International League Against
Epilepsy [ILAE] classification of seizures),7 and were
receiving 1-2 AEDs. Note that in the 2017 ILAE classi-
fication of seizure types, the term “focal” replaces the
1981 term “partial-onset.”8 Key inclusion and exclusion
criteria have been previously published.1,2 If patients
were receiving 2 AEDs at baseline, only one could be a
sodium channel inhibitor (defined as CBZ, LTG, OXC,
or PHT), and only one could be in the upper dose range
(defined as greater than approximately two-thirds of its
defined daily dose [the assumed average maintenance
dose per day for a drug used for its main indication in
adults9]).
2.3 | Study design
Study designs (Figure S1) and statistical methods (includ-
ing details of sample size determination) were identical for
both studies.1,2 Briefly, after an 8-week baseline period, eli-
gible patients were randomized 2:1 to receive oral ESL
(1600 mg or 1200 mg tablets once daily), and began the
18-week, dose-blind treatment period (2-week ESL titra-
tion, 6-week baseline AED taper [concomitant AEDs with-
drawn], 10-week ESL monotherapy).
2.3.1 | Primary endpoint
The primary efficacy endpoint was the proportion (%) of
patients meeting ≥1 of 5 exit criteria (signifying worsening
seizure control) over the 16-week study period (between
the start of the baseline AED taper period [week 2] and the
end of the ESL monotherapy period [week 18]).
2.3.2 | Secondary endpoints
Secondary efficacy endpoints included change in standard-
ized seizure frequency (SSF; seizures per 28 days) from
baseline, and responder rate (proportion of patients with
≥50% reduction in SSF from baseline), for the 18-week
dose-blind treatment period.
2.3.3 | Safety and tolerability
Investigator-reported AEs were coded using the Medical
Dictionary for Regulatory Activities, version 13.1. TEAEs
were defined as any AE that occurred on or after the first
dose of study drug; TEAEs leading to discontinuation
(DCAEs) were defined as any TEAE that led to discontinu-
ation of the study drug. Treatment-emergent serious AEs
(SAEs) were reported separately by the investigators.
2.4 | Study populations and statistical
analyses
Individual patient data from studies 045 and 046 were
pooled, as previously reported,10 and a post hoc explora-
tory analysis was conducted. The pooled intent-to-treat
(ITT) population for the 2 trials comprised all randomized
patients who received ≥1 dose of study drug. The ITT pop-
ulation was used to evaluate patient disposition, overall
baseline demographics and characteristics, and safety out-
comes. The efficacy population (ie, all ITT patients who
entered the baseline AED taper period) was used to evalu-
ate efficacy outcomes.
Endpoints were analyzed for subgroups of patients who
were taking baseline AED regimens that included CBZ,
and separately for those taking regimens that included any
VGSC inhibitor (CBZ, LTG, OXC, or PHT), compared
with those who were taking other AEDs during the base-
line period. Throughout this article, these subgroups are
described by the terms “+CBZ” or “CBZ,” and
“+VGSCi” (VGSC inhibitor) or “VGSCi.”
Both studies used an historical control comparator, as
proposed by French et al., 2010.3 The historical control
exit rate was determined from the placebo/pseudo-placebo
groups of 8 historical conversion-to-monotherapy trials.
The lower bound of the 95% prediction interval of the
overall exit rate (ie, 65.3% at 112 days) was used as the
exit threshold for a single study. Cumulative exit rates and
95% confidence intervals (CIs) at 112 days were estimated
using Kaplan-Meier (KM) methodology for each ESL dose
group, and according to baseline CBZ/VGSCi use. To
examine the potential effects of baseline CBZ and VGSCi
use, an analysis of exit rate was conducted using a Cox
proportional hazards (PH) regression model, including
baseline CBZ/VGSCi use as a covariate. The potential
effect of baseline CBZ dose on exit rate was further inves-
tigated using a PH regression model with total daily base-
line CBZ dose as a covariate.
Statistical summaries and analyses were performed to
compare baseline demographic and clinical characteristics,
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safety, and efficacy data between subgroups. All statistical
procedures were performed using SAS version 9.2 (SAS
Institute, Cary, NC, USA). All statistical tests were 2-
sided.
3 | RESULTS
3.1 | Patients
The ITT population comprised 365 patients (ESL 1600 mg,
n = 242; ESL 1200 mg, n = 123) and the efficacy popula-
tion comprised 332 patients (ESL 1600 mg, n = 218; ESL
1200 mg, n = 114).
Overall, 27% of patients (ITT and efficacy populations)
were taking CBZ at baseline. Patient demographics and
baseline characteristics were generally well balanced
between the +CBZ and CBZ subgroups (Table 1). In
the efficacy population, 81 patients converted to ESL
monotherapy from CBZ alone, and 10 patients converted
from CBZ taken in combination with another baseline
AED; 241 patients did not take CBZ during the baseline
period. The +VGSCi ITT subgroup comprised 212
patients (58% of the total; ESL 1600 mg, n = 133; ESL
1200 mg, n = 79), 47% of whom were taking CBZ dur-
ing the baseline period. The VGSCi ITT subgroup com-
prised 153 patients (ESL 1600 mg, n = 109; ESL
1200 mg, n = 44).
Overall, 139 patients (38.1%; ITT population) discon-
tinued the study early (+CBZ, 41%; CBZ, 37%; reasons
for discontinuation are shown in Figure S2). The rate of
early discontinuation was 41% for the +CBZ subgroup
and 37% for the CBZ subgroup; except for “met one of
five exit criteria” (discussed in the “Primary endpoint”
section), there were no clear differences between groups
in reasons for early discontinuation. The rates of early
discontinuation in the + and VGSCi subgroups were
comparable to those in the + and CBZ subgroups
(+VGSCi, 41%; VGSCi, 34%). For the +CBZ group,
the rate of study discontinuation during the titration per-
iod was greater for patients taking ESL 1600 mg (12%)
versus 1200 mg (5%), whereas during the baseline AED
taper period discontinuation rates were comparable for
both dose groups (1600 mg, 20%; 1200 mg, 21%); dis-
continuation rates during the monotherapy period were
lower for patients taking ESL 1600 mg (7%) versus
1200 mg (21%). For the CBZ group, discontinuation
rates during the titration and baseline AED taper periods
were comparable between dose groups (titration: 1600 mg
9%, 1200 mg 8%; baseline AED taper: 1600 mg 15%,
1200 mg 18%), whereas discontinuation rates during the
monotherapy period were slightly higher for 1200 mg
(16%) than for 1600 mg (11%).
3.2 | Efficacy
3.2.1 | Primary endpoint
The KM-estimated exit rate was higher for patients taking
CBZ or VGSCi at baseline than for those who were not,
for both ESL doses (Figure 1A). For +CBZ and CBZ, as
well as for +VGSCi and VGSCi, the upper 95% confi-
dence limits (UCLs) of the exit rates for both ESL doses
were lower than the historical control threshold (65.3%3).
The overall hazard ratios for study exit rate were
1.49 (95% CI 0.93-2.39; P = .10) for the +CBZ versus
CBZ groups, and 1.27 (95% CI 0.79-2.04; P = .33) for
the +VGSCi versus VGSCi groups, indicating that
although the risk of study exit was higher for the +CBZ/
VGSCi groups than for the CBZ/VGSCi groups, baseline
use of CBZ or VGSCi had no significant effect on the risk
of study exit, for either ESL dose group. In addition, time
to study exit was similar between the +CBZ and CBZ
groups. Furthermore, when the few patients taking CBZ in
the upper dose range (>1200 mg/day, the maximum recom-
mended maintenance dose for most patients11) were
excluded from the analysis, the association between total
daily CBZ dose (during baseline) and exit rate was not sta-
tistically significant (P = .09); when patients taking CBZ
doses >1200 mg/day were included in the analysis, the
association was statistically significant (P = .04).
3.2.2 | Secondary endpoints
Median reductions (%) in SSF between baseline and the
18-week treatment period (2-week titration, 6-week AED
taper, and 10-week monotherapy) were apparent in the
+CBZ, CBZ, +VGSCi and VGSCi groups (Figure 1B).
The magnitude of seizure reduction was lower for patients
who converted from CBZ or VGSCi than for those who
did not (CBZ: 23.5 and 30.8 percentage-point difference,
in the 1600 mg and 1200 mg groups, respectively; VGSCi:
19.8 and 21.8 percentage-point difference, respectively;
Figure 1B). Similarly, responder rates (proportion of
patients with ≥50% reduction in SSF) during the 18-week
treatment period were lower in the +CBZ versus the CBZ
group (ESL 1600 mg, 22.2% vs. 49.4%; 1200 mg, 18.9%
vs. 44.2%) and lower in the +VGSCi group versus the
VGSGi group (ESL 1600 mg, 35.0% vs. 52.5%;
1200 mg, 28.8% vs. 48.8%) (Figure 1C). In the +CBZ
group, no patients were seizure-free for the 18-week treat-
ment period, whereas 11 patients in the CBZ group (ESL
1600 mg, 8 [4.9%]; 1200 mg, 3 [3.9%]) became seizure-
free. The rate of seizure freedom was similar in the
+VGSCi and VGSCi groups (ESL 1600 mg, 3.4% vs.
4.0%; 1200 mg, 1.4% vs. 4.9%). The proportions of
patients with a ≥25% increase in seizure frequency between
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baseline and the 18-week treatment period were 14.3% in
the +CBZ group, 12.9% in the CBZ group, 15.3% in the
+VGSCi group, and 10.7% in the VGSCi group.
3.3 | Safety
During the 18-week dose-blind treatment period, overall
TEAE incidence was 75.0% in the +CBZ group and
80.0% in the CBZ group, and most TEAEs were clas-
sified as mild or moderate in severity. Incidences of
some individual TEAEs differed between the 2 groups
(Table 2, Figure 2); dizziness and somnolence were
reported more frequently in the +CBZ group, and nau-
sea, nasopharyngitis, and back pain more frequently in
the CBZ group (Figure 2). The incidences of dizziness,
somnolence, nausea, fatigue, and blurred vision were
higher during the titration period than during the
monotherapy period, in both the +CBZ and CBZ
groups (Table 2). DCAEs occurred in similar proportions
of the +CBZ and CBZ groups (Table 2). No specific
TEAE led to treatment discontinuation by >5% of
patients, in either dose group. The overall incidence of
SAEs was numerically higher in the +CBZ group than
in the CBZ group (Table 2).
TABLE 1 Baseline demographic and clinical characteristics, by baseline CBZ use (ITT population)
+CBZ CBZ
ESL 1200 mg (n = 39) ESL 1600 mg (n = 61) ESL 1200 mg (n = 84) ESL 1600 mg (n = 181)
Age, years; median (range) 33.0 (16-64) 40.0 (20-67) 39.0 (16-67) 38.0 (16-68)
Gender, male; n (%) 23 (59.0) 30 (49.2) 39 (46.4) 83 (45.9)
Race, n (%)
White 33 (84.6) 52 (85.2) 73 (86.9) 149 (82.3)
Black or African American 3 (7.7) 2 (3.3) 6 (7.1) 17 (9.4)
Asian 0 1 (1.6) 1 (1.2) 3 (1.7)
Other 3 (7.7) 6 (9.8) 4 (4.8) 12 (6.6)
Hispanic or Latino ethnicity, n (%) 6 (15.4) 9 (14.8) 9 (10.7) 16 (8.8)
Region, n (%)
USA 23 (59.0) 38 (62.3) 56 (66.7) 113 (62.4)
Non-USA 16 (41.0) 23 (37.7) 28 (33.3) 68 (37.6)
BMI, kg/m2; median (range) 26.3 (17.6-59.4) 27.3 (18.4-65.0) 26.5 (17.4-47.3) 26.2 (16.9-109.2)
Weight, kg; mean (SD) 83.3 (24.7) 83.4 (26.0) 81.5 (22.8) 80.8 (22.6)
Baseline AEDs used by ≥15% patients,a n (%)
Carbamazepine 39 (100.0) 61 (100.0) 0 0
Lamotrigine 0 0 23 (27.4) 37 (20.4)
Levetiracetam 3 (7.7) 5 (8.2) 27 (32.1) 56 (30.9)
Valproic acid 1 (2.6) 3 (4.9) 15 (17.9) 52 (28.7)
Number of AEDs used at baseline,a n (%)
1 31 (79.5) 46 (75.4) 60 (71.4) 116 (64.1)
2 8 (20.5) 15 (24.6) 24 (28.6) 65 (35.9)
SSF; median (range) 6.5 (2.5-19)b 7.7 (1-29)c 5.5 (1.9-36)d 7.7 (1.9-47)e
Patients with secondarily
generalized seizures
present at baseline, n (%)
13 (33.3) 15 (24.6) 23 (27.4) 55 (30.4)
AED, antiepileptic drug; BMI, body mass index; CBZ, carbamazepine; ESL, eslicarbazepine acetate; ITT, intent-to-treat; SD, standard deviation; SSF, standardized
seizure frequency; USA, United States of America.
Percentages are calculated based on the number of patients with available data in the ITT population in each subgroup.
aAn AED was considered to be used during the baseline period if it was started at any time prior to the first dose of the study drug and continued into the titration
period.
bEfficacy population: n = 37.
cEfficacy population: n = 54.
dEfficacy population: n = 77.
eEfficacy population: n = 162.
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The overall incidence of TEAEs during the 18-week
treatment period was 80.7% in the +VGSCi subgroup and
75.8% in the VGSCi subgroup. There were some differ-
ences in the incidences of individual TEAEs between the 2
subgroups, and between treatment periods (Table 3). The
incidence of dizziness was 8% higher in the +VGSCi sub-
group (25.0%) than the VGSCi subgroup (17.0%), an
effect that was dose related (1200 mg, ~6% higher;
1600 mg, ~10% higher); no other incidences differed by
>5% between subgroups. DCAEs occurred in 13.7% of
patients in the +VGSCi subgroup and 11.8% in the
VGSCi subgroup (Table 3). The incidence of individual
DCAEs was <5% in both dose groups. The overall inci-
dence of SAEs was numerically higher in the +VGSCi sub-
group (6.1%) than the VGSCi subgroup (5.2%) (Table 3).
In the +VGSCi subgroup, no SAE was reported in >1
patient taking either dose of ESL. In the VGSCi sub-
group, hyponatremia was reported as a SAE in 2 patients
(1.8%), both taking ESL 1600 mg once daily. Status
epilepticus occurred in 1 patient (ESL 1600 mg, +CBZ/
+VGSCi subgroups). Injury (joint injury) occurred in 1
patient (ESL 1200 mg, CBZ/VGSCi subgroups) and
was classified as potentially related to ESL.
4 | DISCUSSION
This analysis shows that in patients with treatment-resistant
focal seizures, conversion to ESL from baseline AED regi-
mens including CBZ did not lead to a significantly higher
rate of study exit, or more side effects, than conversion
from treatment regimens that did not include CBZ. How-
ever, it was apparent that the magnitudes of improvement
(ie, reduction) in seizure frequency and responder rates
with ESL were numerically lower for patients who were
taking baseline CBZ than for those who were not. A simi-
lar pattern of results was apparent when the data were ana-
lyzed according to whether patients were taking any of the
4 specified putative VGSC inhibitors (CBZ, LTG, OXC, or
PHT) immediately prior to converting to ESL monother-
apy. This suggests that the treatment effects apparently
related to prior CBZ use may not have been specific to
CBZ, but related to its MoA. Further research is warranted
to assess whether MoA should be considered when switch-
ing from one AED to another.
The primary endpoint of studies 045 and 046 was the
proportion (%) of patients meeting one or more exit criteria
signifying worsening seizure control, between the start of
the baseline AED taper period and the end of the
monotherapy period.1,2 The hazard ratio for study exit rate
for +CBZ vs CBZ was 1.49 (P = .10); so, although there
was a trend toward a higher rate of study exit for +CBZ,
difference in exit rates were not statistically significant
FIGURE 1 A, Kaplan-Meier estimates of exit rate, B, median
reduction in SSF,a and C, 50% responder rate,a by baseline CBZ use.
aBetween baseline and the 18-week dose-blind treatment period. CBZ,
carbamazepine; CI, confidence interval; ESL, eslicarbazepine acetate;
SSF, standardized seizure frequency (seizures per 28 days)
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TABLE 2 Overall incidence of TEAEs, incidences of individual TEAEsa and SAEs according to use of CBZ at baseline, during each
treatment period (ITT population)
Treatment period TEAE, n (%)
+CBZ CBZ
ESL 1200 mg ESL 1600 mg ESL 1200 mg ESL 1600 mg
18-week dose-blind treatment period n 39 61 84 181
Any TEAE 24 (61.5) 51 (83.6) 66 (78.6) 146 (80.7)
Mild 8 (20.5) 22 (36.1) 30 (35.7) 66 (36.5)
Moderate 15 (38.5) 24 (39.3) 32 (38.1) 69 (38.1)
Severe 1 (2.6) 5 (8.2) 4 (4.8) 11 (6.1)
Headache 6 (15.4) 15 (24.6) 19 (22.6) 43 (23.8)
Dizziness 8 (20.5) 19 (31.1) 16 (19.0) 36 (19.9)
Nausea 1 (2.6) 6 (9.8) 12 (14.3) 20 (11.0)
Fatigue 4 (10.3) 7 (11.5) 13 (15.5) 19 (10.5)
Nasopharyngitis 3 (7.7) 2 (3.3) 8 (9.5) 21 (11.6)
Somnolence 5 (12.8) 13 (21.3) 4 (4.8) 20 (11.0)
Back pain 1 (2.6) 2 (3.3) 12 (14.3) 10 (5.5)
Vomiting 2 (5.1) 4 (6.6) 6 (7.1) 11 (6.1)
Blurred vision 2 (5.1) 5 (8.2) 5 (6.0) 11 (6.1)
Diarrhea 1 (2.6) 3 (4.9) 6 (7.1) 8 (4.4)
Insomnia 2 (5.1) 2 (3.3) 5 (6.0) 9 (5.0)
Anxiety 4 (10.3) 3 (4.9) 1 (1.2) 5 (2.8)
Vertigo 1 (2.6) 4 (6.6) 1 (1.2) 2 (1.1)
Bronchitis 2 (5.1) 3 (4.9) 0 1 (0.6)
Any SAE 2 (5.1) 6 (9.8) 3 (3.6) 10 (5.5)
Any DCAE 1 (2.6) 13 (21.3) 9 (10.7) 24 (13.3)
Titration period n 39 61 84 181
Any TEAE 16 (41.0) 42 (68.9) 49 (58.3) 105 (58.0)
Dizziness 5 (12.8) 14 (23.0) 13 (15.5) 21 (11.6)
Headache 2 (5.1) 9 (14.8) 6 (7.1) 23 (12.7)
Fatigue 3 (7.7) 4 (6.6) 9 (10.7) 14 (7.7)
Nausea 0 4 (6.6) 6 (7.1) 11 (6.1)
Somnolence 3 (7.7) 12 (19.7) 4 (4.8) 11 (6.1)
Blurred vision 1 (2.6) 5 (8.2) 3 (3.6) 4 (2.2)
Taper/conversion period n 37 54 77 164
Any TEAE 14 (37.8) 31 (57.4) 43 (55.8) 94 (57.3)
Headache 4 (10.8) 6 (11.1) 8 (10.4) 21 (12.8)
Dizziness 3 (8.1) 6 (11.1) 5 (6.5) 18 (11.0)
Nausea 1 (2.7) 2 (3.7) 2 (2.6) 11 (6.7)
Fatigue 2 (5.4) 3 (5.6) 2 (2.6) 5 (3.0)
Monotherapy period n 30 42 63 139
Any TEAE 13 (43.3) 27 (64.3) 39 (61.9) 80 (57.6)
Headache 1 (3.3) 9 (21.4) 9 (14.3) 12 (8.6)
Back pain 1 (3.3) 1 (2.4) 5 (7.9) 8 (5.8)
Nasopharyngitis 2 (6.7) 1 (2.4) 5 (7.9) 7 (5.0)
Dizziness 1 (3.3) 3 (7.1) 1 (1.6) 7 (5.0)
Bold text represents total numbers/proportions of TEAEs, SAEs and DCAEs; individual TEAEs are not bold. CBZ, carbamazepine; DCAE, TEAE leading to discon-
tinuation; ESL, eslicarbazepine acetate; ITT, intent-to-treat; SAE, serious adverse event; TEAE, treatment-emergent adverse event.
aReported for ≥5% of patients in the total group for +CBZ or CBZ, during the 18-week dose-blind treatment period.
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between the 2 groups. Baseline use of any VGSC-blocking
AED (CBZ, LTG, OXC, or PHT) also had no significant
effect on risk of study exit (hazard ratio = 1.27; P = .33).
Similarly, a pooled analysis of 8 previously completed con-
version-to-AED monotherapy studies (comprising the his-
torical control comparator described by French, et al. 2010)
showed that, although baseline CBZ use increased the haz-
ard rate for study exit (by 8%), withdrawal from CBZ did
not statistically significantly increase the likelihood of
study exit (P = .56).3 It is of note that in French et al.,3
the hazard rate for study exit was calculated from pooled
data and did not focus on switching between AEDs with
the same primary MoA. In the current analysis, when
patients taking CBZ in the upper dose range were
excluded, total daily CBZ dose did not significantly affect
the risk of study exit. However, when patients taking CBZ
doses >1200 mg/day were included in the analysis, the
association between total daily CBZ dose and exit rate was
statistically significant.
A previous pooled analysis of data from studies 045
and 046 showed that patients from the United States were
significantly more likely to exit the studies (due to seizure
worsening) than patients from countries outside of the Uni-
ted States, potentially due to the U.S. patients having more
severe epilepsy at baseline.10 It is therefore important to
note that in the current analysis, the proportion of U.S. and
non-U.S. patients was similar between the +CBZ and
CBZ groups.
Concomitant use of CBZ and ESL has been evaluated
previously in a pooled analysis of data from 3 phase III
trials of adjunctive ESL.12 This analysis showed that
adjunctive ESL (800 and 1200 mg) was effective in
reducing seizure frequency in patients with treatment-
resistant focal seizures, whether or not they were taking
concomitant CBZ; although, improvements in efficacy
were somewhat greater in patients who were not taking
concomitant CBZ (which may reduce plasma eslicar-
bazepine concentrations by 20%-30%).4 In the current
analysis, improvements in seizure frequency were appar-
ent, although less marked in the +CBZ group than in the
CBZ group, perhaps owing in part to the fact that the
analysis period included 10 weeks when the patients were
taking ESL as monotherapy, without CBZ. We speculate
that, due to CBZ’s potent effect on VGSC inhibition
(which targets the key step in the propagation of action
potentials during seizures), conversion from CBZ (alone
or with other AEDs) might generally decrease the likeli-
hood of further seizure improvements compared with con-
version from other baseline AEDs. Improvements in
seizure frequency were also less marked in the +VGSCi
subgroup than in the VGSCi subgroup, suggesting that
the same may also be true for LTG, OXC, and PHT,
FIGURE 2 Differences in TEAEa incidenceb between patients who were or were not taking CBZ during the baseline period (ITT
population). aTEAEs that were most frequently reported in studies 045 and 046. bDuring the 18-week dose-blind treatment period. Differences in
TEAE incidence were calculated as follows: [incidence +CBZ (%)] - [incidence CBZ (%)]. CBZ, carbamazepine; ITT, intent-to-treat; TEAE,
treatment-emergent adverse event
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TABLE 3 Overall incidence of TEAEs, incidences of individual TEAEsa and SAEs according to VGSCib use at baseline, during each
treatment period (ITT population)
Treatment period TEAE, n (%)
+VGSCi VGSCi
ESL 1200 mg ESL 1600 mg ESL 1200 mg ESL 1600 mg
18-week dose-blind treatment period n 79 133 44 109
Any TEAE 58 (73.4) 113 (85.0) 32 (72.7) 84 (77.1)
Headache 17 (21.5) 33 (24.8) 8 (18.2) 25 (22.9)
Dizziness 17 (21.5) 36 (27.1) 7 (15.9) 19 (17.4)
Fatigue 10 (12.7) 11 (8.3) 7 (15.9) 15 (13.8)
Nausea 6 (7.6) 14 (10.5) 7 (15.9) 12 (11.0)
Somnolence 5 (6.3) 20 (15.0) 4 (9.1) 13 (11.9)
Nasopharyngitis 7 (8.9) 13 (9.8) 4 (9.1) 10 (9.2)
Back pain 10 (12.7) 6 (4.5) 3 (6.8) 6 (5.5)
Hyponatremia 2 (2.5) 5 (3.8) 2 (4.5) 6 (5.5)
Insomnia 4 (5.1) 7 (5.3) 3 (6.8) 4 (3.7)
Blurred vision 5 (6.3) 12 (9.0) 2 (4.5) 4 (3.7)
Vomiting 7 (8.9) 10 (7.5) 1 (2.3) 5 (4.6)
Diarrhea 4 (5.1) 8 (6.0) 3 (6.8) 3 (2.8)
Diplopia 4 (5.1) 8 (6.0) 1 (2.3) 2 (1.8)
Complex partial seizures 3 (3.8) 9 (6.8) 1 (2.3) 2 (1.8)
Any SAE 4 (5.1) 9 (6.8) 1 (2.3) 7 (6.4)
Any DCAE 6 (7.6) 23 (17.3) 4 (9.1) 14 (12.8)
Titration period n 79 133 44 109
Any TEAE 39 (49.4) 87 (65.4) 26 (59.1) 60 (55.0)
Dizziness 12 (15.2) 25 (18.8) 6 (13.6) 10 (9.2)
Headache 6 (7.6) 19 (14.3) 2 (4.5) 13 (11.9)
Somnolence 3 (3.8) 16 (12.0) 4 (9.1) 7 (6.4)
Nausea 2 (2.5) 9 (6.8) 4 (9.1) 6 (5.5)
Blurred vision 3 (3.8) 8 (6.0) 1 (2.3) 1 (0.9)
Taper/conversion period n 73 118 41 100
Any TEAE 38 (52.1) 68 (57.6) 19 (46.3) 57 (57.0)
Headache 10 (13.7) 13 (11.0) 2 (4.9) 14 (14.0)
Dizziness 6 (8.2) 16 (13.6) 2 (4.9) 8 (8.0)
Nausea 1 (1.4) 6 (5.1) 2 (4.9) 7 (7.0)
Monotherapy period n 61 98 32 83
Any TEAE 35 (57.4) 61 (62.2) 17 (53.1) 46 (55.4)
Headache 4 (6.6) 14 (14.3) 6 (18.8) 7 (8.4)
Nasopharyngitis 4 (6.6) 4 (4.1) 3 (9.4) 4 (4.8)
Dizziness 1 (1.6) 4 (4.1) 1 (3.1) 6 (7.2)
Back pain 5 (8.2) 4 (4.1) 1 (3.1) 5 (6.0)
Complex partial seizures 2 (3.3) 6 (6.1) 0 1 (1.2)
Bold text represents total numbers/proportions of TEAEs, SAEs and DCAEs; individual TEAEs are not bold. CBZ, carbamazepine; DCAE, TEAE leading to discon-
tinuation; ESL, eslicarbazepine acetate; ITT, intent-to-treat; LTG, lamotrigine; OXC, oxcarbazepine; PHT, phenytoin; SAE, serious adverse event; TEAE, treatment-
emergent adverse event; VGSCi, voltage-gated sodium channel inhibitor.
aReported for ≥5% of patients in the total group for +VGSCi or VGSCi, during the 18-week dose-blind treatment period.
bCBZ/LTG/OXC.
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perhaps to a lesser extent. It is notable that in a clinical
setting, dose-limiting toxicity is another potential reason
to consider converting from a VGSCi (such as CBZ) to
another AED, including to another VGSCi. Therefore,
individual patient tolerability is an important considera-
tion.
In addition, it is of note that these clinical studies were
not designed to optimize patient outcomes following con-
version to ESL and did not consider the type or dose of
baseline AEDs, or the factors necessitating the conversion
to an alternative therapy. The studies were instead designed
to investigate whether seizure worsening would occur fol-
lowing conversion from 1 or 2 AEDs to ESL monotherapy,
compared with a historical control comparator, as per FDA
requirements at the time of the studies. Patients were
required to follow a fixed conversion protocol when transi-
tioning to ESL monotherapy, without consideration of the
needs of individual patients. It is possible that patients may
have achieved better seizure control if ESL titration and
AED taper rates (as well as the final ESL dose) had been
tailored for individual patients.
Although the interpretation and extrapolation of data
from most, if not all, registration clinical trials to the real-
world setting may be restrained by the nature of controlled
study designs, this issue is of relevance for this analysis, as
all the data from our studies, as well as the French et al
analysis of the historical control trials, used a variant of a
forced conversion protocol. In the real-world clinical set-
ting, careful management of the method of conversion from
CBZ (or other VGSCi) to ESL may result in better out-
comes than those reported here.
The overall incidence of TEAEs was comparable
between the +CBZ and CBZ groups; incidences of dizzi-
ness and somnolence were >5% higher in the +CBZ group
than in the CBZ group, whereas incidences of nausea,
nasopharyngitis, and back pain were >5% higher in the
CBZ group than in the +CBZ group (Figure 2). The rea-
son for these contrasting differences is unknown. The inci-
dence of dizziness was also >5% higher in the +VGSCi
subgroup than the VGSCi subgroup.
Incidences of dizziness, somnolence, nausea, fatigue,
and blurred vision were all higher during the titration per-
iod than during the monotherapy period (in the + and
CBZ and VGSCi groups), suggesting that new-onset
TEAEs are more likely to occur while patients are taking
ESL with existing AED regimens, than after conversion to
ESL monotherapy. The incidence of TEAEs classed as sev-
ere was comparable between the +CBZ and CBZ groups,
whereas the incidence of SAEs was numerically higher in
the +CBZ and +VGSCi groups than in the CBZ and
VGSCi groups, respectively.
In a previous analysis of 3 trials of adjunctive ESL,
overall TEAE incidence was slightly lower for the +CBZ
versus the CBZ group, although dizziness, diplopia,
vomiting, and nausea were reported more frequently in
patients taking ESL and concomitant CBZ than in those
not taking concomitant CBZ.13 Another analysis of the
same data showed that overall TEAE incidence was com-
parable between patients who were or were not concomi-
tantly taking LTG, another VGSC inhibitor (and who
were not taking baseline CBZ or PHT); although, in the
ESL 1200 mg dose group, incidences of dizziness, diplop-
ia, and vertigo were higher among patients taking con-
comitant LTG.14 It is therefore unclear whether the higher
incidences of specific TEAEs that occurred when ESL
was combined with CBZ/other VGSC inhibitors (com-
pared with other AEDs, during the adjunctive studies and
the titration and baseline AED taper periods of the con-
version-to-monotherapy studies) was driven by a possible
pharmacodynamic interaction due to the common MoA
(VGSC inhibition), or there was another unknown reason
or epiphenomenon.
A potential limitation of the current analysis is that dif-
ferences in dose could have had differential effects on tol-
erability outcomes, which would not be detected here. In
addition, although patients were not permitted to use more
than 1 VGSC inhibitor during baseline, use of more than 1
baseline AED (with different MoAs) was permitted and
could affect outcomes; this was not examined in the current
analysis. Another potential limitation is that the +VGSCi
subgroup included patients taking CBZ, as well as patients
taking other VGSC inhibitors (LTG, OXC, and PHT). It is
therefore unclear whether prior use of LTG, OXC, and
PHT alone would have reduced the magnitude of seizure
improvements with ESL (compared with the VGSCi
group), or if the results were driven primarily by seizure
responses in patients who had been taking CBZ. Another
limitation is the post hoc nature of the analyses; statistical
comparisons of TEAE incidences were not prospectively
planned and were therefore described primarily using
descriptive statistics.
The results of the current analysis suggest that conver-
sion to ESL from CBZ, or the other VGSCi analyzed here,
could be a viable treatment strategy, both for patients who
are seeking better tolerability and for those requiring
improved seizure control from the conversion. Although,
further studies would be required to examine long-term tol-
erability with ESL versus CBZ. Patients who converted to
ESL from CBZ were not significantly more likely to exit
the study (due to seizure worsening) than patients who con-
verted to ESL from AED regimens that did not include
CBZ. In fact, ~20% of patients who converted to ESL from
CBZ actually achieved a clinically meaningful response (a
≥50% reduction in seizure frequency) following the conver-
sion. The overall frequency of side effects was similar
between the +CBZ and CBZ groups. Comparable
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outcomes were observed when converting to ESL from
CBZ, LTG, OXC, or PHT; therefore, the above recommen-
dations and considerations will likely be relevant when
converting to ESL from any baseline VGSC inhibitor.
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